Trials / Completed
CompletedNCT02860624
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Efficacy and Safety of Ilaprazole for GERD: A Randomized, Double-Blind, Esomeprazole-Controlled, Phase 3, Multicenter Trial in China
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 550 (actual)
- Sponsor
- Livzon Pharmaceutical Group Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 10 mg ilaprazole | Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks |
| DRUG | 40mg esomeprazole | One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-04-01
- First posted
- 2016-08-09
- Last updated
- 2016-08-09
Source: ClinicalTrials.gov record NCT02860624. Inclusion in this directory is not an endorsement.